Literature DB >> 7827396

Pharmacological management of schizophrenia in older patients.

C Gregory1, P McKenna.   

Abstract

Although antipsychotic drugs are the mainstay of treatment in older patients with schizophrenia, much of the theoretical work underpinning their use is based on evidence gained from younger patients. With respect to dosages, there has been little work comparing plasma concentrations of antipsychotics in older patients with those of younger patients. However, there are well documented changes in the pharmacokinetics of these drugs in the elderly, particularly in their hepatic metabolism and renal excretion. There is also evidence that older patients experience more adverse effects from antipsychotics than younger patients. Such effects include extrapyramidal symptoms, postural hypotension and falls. For these reasons it is recommended that starting doses of antipsychotic drugs in older patients should be in the region of 25 to 50% of that recommended for younger patients, and should be slowly increased. Selection of a particular antipsychotic agent is best made on the basis of individual patient characteristics and the adverse effect profiles of particular drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827396     DOI: 10.2165/00002512-199405040-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  33 in total

1.  D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics.

Authors:  L Farde; F A Wiesel; A L Nordström; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  A chart review study of late-onset and early-onset schizophrenia.

Authors:  G D Pearlson; L Kreger; P V Rabins; G A Chase; B Cohen; J B Wirth; T B Schlaepfer; L E Tune
Journal:  Am J Psychiatry       Date:  1989-12       Impact factor: 18.112

Review 3.  Review: drug-induced parkinsonism in elderly patients.

Authors:  J A Wilson; W J MacLennan
Journal:  Age Ageing       Date:  1989-05       Impact factor: 10.668

4.  Can schizophrenia begin after age 44?

Authors:  P Rabins; S Pauker; J Thomas
Journal:  Compr Psychiatry       Date:  1984 May-Jun       Impact factor: 3.735

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

6.  Negative and deficit symptoms in schizophrenia do respond to neuroleptics.

Authors:  S C Goldberg
Journal:  Schizophr Bull       Date:  1985       Impact factor: 9.306

7.  Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia.

Authors:  L S Pilowsky; D C Costa; P J Ell; R M Murray; N P Verhoeff; R W Kerwin
Journal:  Lancet       Date:  1992-07-25       Impact factor: 79.321

Review 8.  Clozapine: a hypothesised mechanism for its unique clinical profile.

Authors:  B S Bunney
Journal:  Br J Psychiatry Suppl       Date:  1992-05

9.  Treatment of late-life schizophrenia with neuroleptics.

Authors:  D V Jeste; J P Lacro; P L Gilbert; J Kline; N Kline
Journal:  Schizophr Bull       Date:  1993       Impact factor: 9.306

10.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.

Authors:  L Farde; F A Wiesel; S Stone-Elander; C Halldin; A L Nordström; H Hall; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1990-03
View more
  3 in total

Review 1.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

Review 2.  Antipsychotic medications and the elderly: effects on cognition and implications for use.

Authors:  M J Byerly; M T Weber; D L Brooks; L R Snow; M A Worley; E Lescouflair
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Pharmacokinetics of quetiapine in elderly patients with selected psychotic disorders.

Authors:  George E Jaskiw; Per T Thyrum; Matthew A Fuller; Lisa A Arvanitis; Chiao Yeh
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.